CDBIO(SH:688739) Xin Lang Cai Jing·2025-08-26 02:31Group 1 - The core viewpoint of the news is that Chengda Biological has shown a slight increase in stock price and trading volume, with notable financing activities indicating a low level of margin trading compared to historical data [1] - On August 25, Chengda Biological's stock rose by 1.34%, with a trading volume of 158 million yuan, and a net financing purchase of 2.14 million yuan [1] - The total margin balance for Chengda Biological as of August 25 is 212 million yuan, which is 1.72% of its circulating market value, indicating a low financing level compared to the past year [1] Group 2 - As of March 31, Chengda Biological had 25,500 shareholders, a decrease of 2.17% from the previous period, while the average circulating shares per person increased by 2.22% to 7,417 shares [2] - For the first quarter of 2025, Chengda Biological reported a revenue of 358 million yuan, a year-on-year decrease of 1.73%, and a net profit attributable to shareholders of 72.22 million yuan, down 11.35% year-on-year [2] - Since its A-share listing, Chengda Biological has distributed a total of 1.492 billion yuan in dividends, with 1.075 billion yuan distributed in the last three years [2]